BioStock: PHI’s CEO reflects on the Company’s momentum

Medtech company PHI has experienced a dynamic year, with multiple significant advancements resulting in a 230 per cent surge in the company’s stock price so far this year.

BioStock reached out to PHI’s CEO, Patrik Eschricht, to delve into what latest developments have contributed to the heightened enthusiasm surrounding the company.

Read the full interview with Patrik Eschricht on